Showing 1921-1930 of 3223 results for "".
- Alcon Introduces Virtual Reality Surgical Training Technologyhttps://modernod.com/news/alcon-introduces-virtual-reality-surgical-training-technology/2480761/Alcon announced the launch of the Alcon Fidelis Virtual Reality (VR) Ophthalmic Surgical Simulator, a portable VR tool for cataract surgeons-in-training. As part of the Alcon Experience Academy, the VR simulator of
- Actress Kate Walsh Teams Up with Alcon for Dry Eye Campaignhttps://modernod.com/news/actress-kate-walsh-teams-up-with-alcon-for-dry-eye-campaign/2480754/Alcon announced a partnership with actress Kate Walsh, best known for her roles in Grey’s Anatomy and Emily in Paris, to share her journey with dry eye around the launch of its Systane Complete Preservative-Free Lubricant Eye Drops. As part of the new
- Alimera Exhibits Continued Growth and Expansion With New Branding and Office Relocationhttps://modernod.com/news/alimera-exhibits-continued-growth-and-expansion-with-new-branding-and-office-relocation/2480750/Alimera Sciences announced that the company has launched new corporate branding and moved its global headquarters to a new, state-of-the-art facility. Alimera refreshed its corporate brand for the first time in the company’s two-decade history to better represent its current
- Allergan Announces Positive Topline Phase 3 Results Evaluating Twice-Daily Administration of Vuity in Adults with Presbyopiahttps://modernod.com/news/allergan-announces-positive-topline-phase-3-results-evaluating-twice-daily-administration-of-vuity-in-adults-with-presbyopia/2480749/Allergan announced that the phase 3 VIRGO trial evaluating the safety and efficacy of investigational twice-daily administration of Vuity (pilocarpine HCl ophthalmic solution) 1.25% in adults with presbyopia met its primary efficacy endpoint, improving near vision without compromising distan
- Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY-2 Trial in Patients with Dry Eye Diseasehttps://modernod.com/news/aldeyra-therapeutics-announces-completion-of-enrollment-in-phase-3-tranquility-2-trial-in-patients-with-dry-eye-disease/2480746/Aldeyra Therapeutics announced completion of enrollment in the phase 3 TRANQUILITY-2 trial of 0.25% reproxalap ophthalmic solution in patients with dry eye disease. The multicenter, double-masked, parallel-group TRANQUILITY-2 trial enrolled 361 patients randomized to receive either
- Eyenuk Joins the Population Health Alliance, Paving Way for Autonomous AI to Improve Diabetes Complicationshttps://modernod.com/news/eyenuk-joins-the-population-health-alliance-paving-way-for-autonomous-ai-to-improve-diabetes-complications/2480690/Population Health Alliance (PHA) announced that Eyenuk has joined the organization as a member. Eyenuk is a global artificial intelligence (AI) medical technology and services company and a provider of real-world applications for AI Eye Screening and AI Predictive Biomarkers.
- Alcon Launches Clareon IOL Portfolio in the UShttps://modernod.com/news/alcon-launches-clareon-iol-portfolio-in-the-us/2480677/Alcon announced the launch of the Clareon family of IOLs in the United States. Utilizing an advanced IOL material, Clareon is designed to deliver consistent visual outcomes and clarity that lasts.[1-7] The Clareon clarity is born out of a glistening-free IOL material that has among
- Johnson & Johnson Vision Receives FDA Approval for First Drug-Eluting Contact Lens—Acuvue Theravision with Ketotifenhttps://modernod.com/news/johnson-johnson-vision-receives-fda-approval-for-first-drug-eluting-contact-lens-acuvue-theravision-with-ketotifen/2480676/Johnson & Johnson Vision Care announced that the FDA has approved Acuvue Theravision with Ketotifen (etafilcon A drug-eluting contact lens with ketotifen), the first drug-eluting contact lens. Each lens contains 19 mcg ketotifen, an antihistamine. Acuv
- Lensar Submits FDA 510(k) Application for ALLYhttps://modernod.com/news/lensar-announces-us-food-and-drug-administration-acceptance-of-510k-submission-for-ally/2480671/Lensar announced that the FDA has accepted its 510(k) submission for its next-generation ALLY Adaptive Cataract Treatment System for review. The submission is the first stage of a planned, two-step commercial release s
- Allergan to Present Data From Durysta and Xen Gel Stent at the 2022 American Glaucoma Society (AGS) Annual Meetinghttps://modernod.com/news/allergan-to-present-data-from-durysta-and-xen-gel-stent-at-the-2022-american-glaucoma-society-ags-annual-meeting/2480663/Allergan announced new data to be presented from it